Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

NIH

Sponsor class

Conditions

Ganglioneuroblastoma
High Risk Neuroblastoma

Interventions

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Cyclophosphamide
DRUG: Dexrazoxane
BIOLOGICAL: Dinutuximab
DRUG: Doxorubicin
DRUG: Etoposide
RADIATION: External Beam Radiation Therapy
DRUG: Isotretinoin
DRUG: Melphalan
BIOLOGICAL: Sargramostim
DRUG: Thiotepa
DRUG: Topotecan
DRUG: Vincristine

Sponsor

National Cancer Institute (NCI)